A Phase 1 Study of Elranatamab With Iberdomide in People With Multiple Myeloma


Full Title

A Phase 1b, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma


Researchers want to find the best dose of iberdomide that can be given with elranatamab in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.

Iberdomide targets a protein called cereblon that plays a role in myeloma cell growth. This targeting action may help kill myeloma cells and increase the immune response. Iberdomide is taken orally (by mouth).

Elranatamab is a standard treatment for multiple myeloma that helps boost the immune system to fight cancer. Giving it with iberdomide may improve the immune response. Elranatamab is given as an injection under the skin.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that came back or keeps growing even after treatment.
  • Have recovered from the serious side effects of prior therapies before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Alexander Lesokhin’s office at 646-608-2091.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID